Key result
Preoperative statin exposure was associated with reduced 30-day perioperative mortality after CABG surgery compared to no statins (0.4% vs 0.8%; HR 0.40, 95% CI 0.20-0.80).
Why the study?
Do preoperative cardiovascular drugs (statins, ACE inhibitors, alpha-2 agonists, CCBs, beta-blockers) reduce perioperative mortality in patients undergoing CABG surgery?
Observational (n=16,192)
Yes
Do preoperative cardiovascular drugs (statins, ACE inhibitors, alpha-2 agonists, CCBs, beta-blockers) reduce perioperative mortality in patients undergoing CABG surgery?
Preoperative statin therapy, specifically simvastatin 40 mg, is associated with significantly reduced 30-day and 6-month mortality after CABG surgery, whereas other cardiovascular drugs do not show consistent protective effects.
Answers are grounded in this paper and cite their sources.
Preoperative statins were associated with lower CABG mortality; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Statins reduce risk from coronary artery bypass graft (CABG) surgery, but the influence of angiotensin-converting enzyme inhibitors, alpha-2 adrenergic agonists, calcium channel blockers and beta-blockers is less clear. OBJECTIVES: We investigated the association of each of these drugs with perioperative risk, accounting for different confounders, and evaluated the class, dose-response and long-term protective effect of statins. DESIGN: A retrospective analysis of observational data. SETTING: United Kingdom. PATIENTS: Sixteen thousand one hundred and ninety-two patients who underwent CABG surgery during the period 01 January 2004 to 31 December 2013 and contributed data to Primary Care Clinical Practice Research Datalink. EXPOSURE VARIABLES: Cardiovascular drugs. OUTCOME MEASURE: Perioperative mortality within 30 days of surgery. STATISTICAL ANALYSIS: Five multivariable logistic regression models and a further Cox regression model were used to account for preexisting cardiovascular and other comorbidities along with lifestyle factors such as BMI, smoking and alcohol use. RESULTS: Exposure to statins was most prevalent (85.1% of patients), followed by beta-blockers (72.8%), angiotensin-converting enzyme inhibitors (60.5%), calcium channel blockers (42.8%) and alpha-2 adrenergic agonists (1.2%). The mortality rate was 0.8% in patients not prescribed statins and 0.4% in those on statins. Statins were associated with a statistically significant reduced perioperative mortality in all five logistic regression models with adjusted odds ratios (OR) (95% confidence interval, 95% CI) ranging from 0.26 (0.13 to 0.54) to 0.35 (0.18 to 0.67). Cox regression for perioperative mortality [adjusted hazard ratio (95% CI) 0.40 (0.20 to 0.80)] and 6-month mortality [adjusted hazard ratio (95% CI) 0.63 (0.42 to 0.92)] produced similar results. Of the statin doses tested, only simvastatin 40 mg exerted protective effects. The other cardiovascular drugs lacked consistent effects across models. CONCLUSION: Statins appear consistently protective against perioperative mortality from CABG surgery in multiple models, an effect not shared by the other cardiovascular drugs. Further data are needed on whether statins exert class and dose-response effects.
No takes yet. Share an insight, caveat, or question.
Venkatesan et al. (2015) conducted an observational in Coronary artery bypass graft (CABG) surgery (n=16,192). Statins vs. No statins was evaluated on Perioperative mortality within 30 days of surgery (HR 0.40, 95% CI 0.20-0.80). Preoperative statin exposure was associated with reduced 30-day perioperative mortality after CABG surgery compared to no statins (0.4% vs 0.8%; HR 0.40, 95% CI 0.20-0.80).
Synapse has enriched 10 related papers. Consider them for comparative context: